PriceTargets.com logo

Mustang Bio - MBIO Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $2.00
  • Forecasted Upside: 925.12%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.20 As of 11/25/2024 01:00 AM ET
▼ -0.01 (-4.88%)

This chart shows the closing price for MBIO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Mustang Bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MBIO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MBIO

Analyst Price Target is $2.00
▲ +925.12% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Mustang Bio in the last 3 months. The average price target is $2.00, with a high forecast of $2.00 and a low forecast of $2.00. The average price target represents a 925.12% upside from the last price of $0.20.

This chart shows the closing price for MBIO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Mustang Bio. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/4/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/2/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/1/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/29/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/29/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/27/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/13/2024HC WainwrightLower TargetBuy ➝ Buy$25.00 ➝ $2.00
8/24/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$18.00
8/15/2023BTIG ResearchLower TargetBuy ➝ Buy$20.00 ➝ $16.00
8/15/2023HC WainwrightReiterated RatingBuy ➝ Buy$25.00
6/16/2023BTIG ResearchBoost Target$4.00 ➝ $20.00
5/26/2023B. RileyBoost Target$4.00 ➝ $10.00
3/30/2023HC WainwrightReiterated RatingBuy
12/2/2022B. RileyReiterated RatingBuy
11/17/2022OppenheimerLower Target$60.00
11/16/2022BTIG ResearchLower TargetBuy$120.00 ➝ $60.00
7/14/2022B. RileyLower Target$75.00 ➝ $60.00
5/23/2022B. RileyLower Target$90.00 ➝ $75.00
5/20/2022HC WainwrightReiterated RatingBuy$105.00
3/24/2022HC WainwrightReiterated RatingBuy$105.00
1/24/2022B. RileyLower TargetBuy$195.00 ➝ $90.00
12/17/2021HC WainwrightReiterated RatingBuy$105.00
12/8/2021BTIG ResearchReiterated RatingBuy$165.00
11/15/2021Cantor FitzgeraldReiterated RatingOverweight
8/3/2021HC WainwrightReiterated RatingBuy$105.00
6/14/2021BTIG ResearchReiterated RatingBuy$165.00
5/17/2021BTIG ResearchInitiated CoverageBuy$165.00
12/23/2020B. RileyReiterated RatingBuy$195.00
11/9/2020Cantor FitzgeraldReiterated RatingOverweight
10/2/2020B. RileyReiterated RatingBuy
10/2/2020B. RileyInitiated CoverageBuy$135.00
8/11/2020HC WainwrightReiterated RatingBuy$105.00
8/11/2020OppenheimerReiterated RatingBuy
5/12/2020OppenheimerReiterated RatingBuy$225.00 ➝ $195.00
2/18/2020HC WainwrightReiterated RatingBuy$105.00
1/9/2020Cantor FitzgeraldReiterated RatingBuy$105.00
(Data available from 11/25/2019 forward)

News Sentiment Rating

0.14 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/29/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/29/2024
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/28/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/28/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/27/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/26/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/26/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/25/2024

Current Sentiment

  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Mustang Bio logo
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.
Read More

Today's Range

Now: $0.20
Low: $0.20
High: $0.22

50 Day Range

MA: $0.24
Low: $0.21
High: $0.31

52 Week Range

Now: $0.20
Low: $0.13
High: $1.68

Volume

682,758 shs

Average Volume

8,887,189 shs

Market Capitalization

$9.32 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.92

Frequently Asked Questions

What sell-side analysts currently cover shares of Mustang Bio?

The following Wall Street research analysts have issued reports on Mustang Bio in the last twelve months: HC Wainwright.
View the latest analyst ratings for MBIO.

What is the current price target for Mustang Bio?

0 Wall Street analysts have set twelve-month price targets for Mustang Bio in the last year. Their average twelve-month price target is $2.00, suggesting a possible upside of 925.1%. HC Wainwright has the highest price target set, predicting MBIO will reach $2.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $2.00 for Mustang Bio in the next year.
View the latest price targets for MBIO.

What is the current consensus analyst rating for Mustang Bio?

Mustang Bio currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MBIO will outperform the market and that investors should add to their positions of Mustang Bio.
View the latest ratings for MBIO.

What other companies compete with Mustang Bio?

Other companies that are similar to Mustang Bio include Anebulo Pharmaceuticals, Clene, Passage Bio, OKYO Pharma and Lumos Pharma. Learn More about companies similar to Mustang Bio.

How do I contact Mustang Bio's investor relations team?

Mustang Bio's physical mailing address is 377 PLANTATION STREET, WORCESTER MA, 01605. The company's listed phone number is (781) 652-4500 and its investor relations email address is [email protected]. The official website for Mustang Bio is www.mustangbio.com. Learn More about contacing Mustang Bio investor relations.